EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study

Shikha Kini, Vedat Yildiz iD, Darrion Mitchell, Emile Gogineni, John Grecula, David Konieczkowski, Simeng Zhu, Sung Jun Ma, Priyanka Bhateja, Matthew Old, Nolan Seim, Dukagjin M Blakaj und 4 weitere

Thyroid® · 2025-10 · 35 (10) · 1129-1137

DOI: 10.1177/10507256251372191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 03.09.2025. Verfasst von Shikha Kini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Georgetown University, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anaplastic thyroid cancer (ATC) is an aggressive malignancy with a median survival of six months. While immunotherapy (IT) has improved outcomes in other solid tumors, its role in ATC remains unclear. This study evaluated whether receipt of IT was associated with improved overall survival (OS) in the initial treatment of patients with newly diagnosed ATC.

Methods

We performed a retrospective study of patients with metastatic and nonmetastatic ATC from the National Cancer Database (2008–2020) treated with surgery, radiation, chemotherapy, or a combination. Patient outcomes were stratified between those who received IT at any point in their treatment compared with those who did not. The primary outcome was OS, compared between cohorts receiving IT and those who did not. Survival analyses were performed using Kaplan–Meier estimates, long-rank tests, and multivariable models.

Results

Among 3318 patients with ATC, 87 (2.6%) received IT. Rates of surgical resection (46%) and radiation therapy (64% vs. 57%, p = 0.133) were similar across groups. IT recipients were younger (mean = 66.7 vs. 70.2 years, p = 0.005), more often diagnosed in recent years (2017–2019 vs. 2008–2016, p = 0.0001), and more frequently received chemotherapy (65.5% vs. 46.3%, p = 0.0007). Charlson Comorbidity Index scores were similar ( p = 0.551). Median OS was 9.1 months (confidence interval [CI] 7.06–14.9) for those receiving IT versus 3.78 months (CI: 3.52–4.01) for those who did not ( p < 0.005). Five-year OS was 18% (CI: 5–36%) with IT versus 9% (CI: 8–10%) without ( p < 0.0001). Among 23 patients who received trimodality therapy (surgery, IT, and radiation), 5-year OS was 35% (CI: 16–55%) versus 9% in patients who did not.

Conclusions

IT was associated with prolonged survival in patients with ATC, although confounding factors, such as the retrospective design of the study, lack of detailed IT drug details, and sequencing of therapy, preclude definitive conclusions on its efficacy. The efficacy of IT for ATC as a stand-alone treatment is uncertain. Further studies could indicate which combination of therapies best increases OS in patients with ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsImmunotherapyHumansFemaleMaleRetrospective StudiesAgedMiddle AgedDatabases, FactualTreatment OutcomeUnited StatesAged, 80 and overCombined Modality Therapy

Stichwörter der Autor:innen

anaplastic thyroid cancerimmunotherapyradiationsurgery

Autor:innen und Institutionen

  • Georgetown University, Washington, District of Columbia, USA.
  • Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Otolaryngology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

ORCID-Profile: Vedat Yildiz, Vineeth Sukrithan

Zitieren

APA

Kini, S., Yildiz, V., Mitchell, D., Gogineni, E., Grecula, J., Konieczkowski, D., Zhu, S., Ma, S. J., Bhateja, P., Old, M., Seim, N., Blakaj, D. M., Patel, D., Sukrithan, V., Konda, B., & Baliga, S. (2025). Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study. Thyroid®, 35(10), 1129-1137. https://doi.org/10.1177/10507256251372191

Vancouver

Kini S, Yildiz V, Mitchell D, Gogineni E, Grecula J, Konieczkowski D, et al. Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study. Thyroid®. 2025;35(10):1129-1137. doi:10.1177/10507256251372191

BibTeX
@article{Kini2025,
  author = {Kini, Shikha and Yildiz, Vedat and Mitchell, Darrion and Gogineni, Emile and Grecula, John and Konieczkowski, David and Zhu, Simeng and Ma, Sung Jun and Bhateja, Priyanka and Old, Matthew and Seim, Nolan and Blakaj, Dukagjin M and Patel, Dipen and Sukrithan, Vineeth and Konda, Bhavana and Baliga, Sujith},
  title = {Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study},
  journal = {Thyroid®},
  year = {2025},
  volume = {35},
  number = {10},
  pages = {1129--1137},
  doi = {10.1177/10507256251372191}
}
Kostenlos starten →